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ABSTRACT 
 
Bone marrow-derived mesenchymal stem cells (BMSCs) can ameliorate a variety of lung 
diseases such as asthma, lung fibrosis, and acute lung injury by its anti-inflammatory and 
immunmodulatory effects. In this study, we developed a mouse model of bronchiolitis 
obliterans (BO) and evaluated the effects of the intraperitoneal administration of BMSCs on 
lung histopathology and cytokine levels. 
 25 BALB/c mice were divided into four groups; control group (Group I), BO developed 
and 1x106 BMSCs-injected group (Group II), non-BO, 1x106 BMSCs-injected group (Group 
III), and BO developed and saline-injected group (Group IV). Histological and 
immunohistochemical findings of the lung tissue and the migration of BMSCs to the lung 
were evaluated using light and confocal microscopy techniques. 
Confocal microscopy evaluations showed that there was no noteworthy amount of 
BMSCs in the lung tissue of group III while significant amount of BMSCs was detected in 
group II. Wall thicknesses of terminal bronchiole and periterminal bronchiolar collagen 
deposition were significantly lower in group II compared to the group IV (p<0.05). 
Furthermore, according to the immunohistochemical staining results, CD3, CD4, CD8, 
CD20, CD68 and neutrophil elastase positive immune cells of group II were stained more 
positive than group IV cells (p<0.05). IFN-γ IL-2 and TNF-α levels in bronchoalveolar 
lavage fluid (BALF) were significantly lower in group II compared to group IV (p<0.05). 
The findings of this study indicate that intraperitoneally administered BMSCs have potent 
effects on histopatological changes of the lung tissue and cytokine levels in the murine model 
of BO.   
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INTRODUCTION 
 
Bronchiolitis obliterans (BO) is a rare disorder 
characterized histologically by a 
fibrosing/inflammatory process that constricts and 
eventually obliterates the small airways.
1
 The 
functional loss of these airways results in long-term 
wheezing, chronic cough, and often severe respiratory 
distress. Etiological causes of BO include especially 
Mycoplasma and Adenovirus infections (the most 
common cause in children); toxic fume inhalation; 
drugs; and complications in allograft recipients 
undergoing heart-lung, lung and bone marrow 
transplantation (the most common causes in adults).
1,2
 
Patients with BO have poor prognosis and 
significant long-term morbidity is reported in 78% to 
92% of patients.
3,4
 A variety of medications including 
immunosuppressive, anti-inflammatory, and anti-
fibrotic agents such as corticosteroids, calcineurin 
inhibitors, azathioprine, methotrexate, pirfenidone, 
monoclonal antibodies, macrolides, and chloroquine 
have been used.
5-9
 However, these therapeutic 
approaches applied to patients with severe BO 
generally fail and the outcome is usually 
disappointing. These treatment approaches are based 
mainly on supportive care. This failure can be the 
result of delayed diagnosis and there can be 
irreversible fibrotic changes and airway obliteration. 
Mesenchymal stem cells (MSCs), multipotent 
progenitor cells, are readily isolated from bone 
marrow and it is proved that MSCs are useful in the 
regeneration and maintenance of various tissues.
10,11
 
MSCs produce large quantities of bioactive factors, 
which cause immunsupression in T cells as well as 
anti-scarring, angiogenic, anti-apoptotic, and 
regenerative effects. These factors can also suppress 
the production of some cytokines such as TNF-α and 
IFN-γ11,12 Stem cell plasticity refers to the ability of 
some stem cells to give rise to cell types, formerly 
considered outside their normal repertoire of 
differentiation for the location, where they are 
found. Previous studies demonstrated that MSCs can 
show better plasticity than it is known. For instance; it 
is possible to differentiate them into alveolar and 
bronchial epithelium, vascular endothelium, and 
interstitial cell types.
13
 Furthermore, they have 
positive effects on various pulmonary diseases such as 
asthma, acute lung injury/acute respiratory distress 
syndrome, and chronic obstructive pulmonary 
disease.
14-17
 
The purpose of this study was to evaluate the 
migration of allogeneic bone marrow-derived MSCs 
(BMSCs) to the lung tissue upon intraperitoneal 
injection and effects of BMSCs on lung 
histopathology along with TH1 immune responses in 
a murine model of BO. 
 
MATERIALS AND METHODS 
 
Animals and Experimental Procedures  
25, male, BALB/c mice of 6-8 weeks of age were 
equally randomized into four groups as 
following: Control group (Group I) consisted of 
healthy animals (n=5); bronchiolitis obliterans (BO)-
developed and 1x10
6 
allogeneic BMSCs-injected 
group (Group II) (n=7); non-BO and 1x10
6
 allogeneic 
BMSCs-injected group (Group III) (n=7); and BO-
developed and saline-injected group (Group IV) 
(n=7). In BO-developed groups, animals received 20 
µL nitric acid at a concentration of 2% intranasally 
through a volumetric pipette. Furthermore, in non-BO 
groups, animals underwent the same experimental 
procedure but received an intranasal instillation of 
saline solution (0,09 % NaCl).
18 
BO model was 
established eight weeks after the administration of the 
nitric acid. At that time, 1x10
6
 allogeneic BMSCs in 
physiological saline solution were respectively 
administered to group II and III mice by an 
intraperitoneal injection. Saline was also administered 
intraperitoneally to group IV mice. One week after the 
model establishment, all mice were sacrificed and 
tissue harvesting was done (Figure 1). All 
experimental procedures complied with the 
requirements of the Animal Care and Ethics 
Committee of the Dokuz Eylul University. 
 
Isolation and Culture of BMSCs 
Mesenchymal stem cells were isolated from femurs 
and tibias of sacrificed 6 to 8-week-old BALB/c mice. 
Briefly, femurs and tibias were stored in phosphate 
buffered saline (PBS) with 1% penicillin/streptomycin 
(Invitrogen, USA) and the ends of bones were 
carefully removed. Then, 5 mL of Dulbecco's 
modified Eagle's medium (DMEM; Invitrogen, USA) 
including 15% fetal bovine serum and 1% 
penicillin/streptomycin and 2 mM L-glutamine, was 
used to flush cells from femurs by using a 18-gauge 
needle. Bone marrow cells were collected in a falcon 
tube and then centrifuged at 1000 rpm for 10 min. The  
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Figure 1. Time table for the bronchiolitis obliterans (BO) murine model and treatments with bone marrow-derived 
mesenchymal stem cells (MSCs) and saline 
 
 
cell pellet was homogenized in DMEM including 15% 
fetal bovine serum and 1% penicillin/streptomycin 
and 2 mM L-glutamine. Then, cells were transferred 
into 75 cm
2 
culture flasks and incubated at 37°C in a 
humidified atmosphere of 5% carbon dioxide.
19
 
Upon 72 h of incubation, the non-adherent cells 
were removed by changing the medium. The medium 
was completely replaced every 3 days and non-
adherent cells were discarded. When cells became 70-
80% confluent, adherent cells were detached from the 
flasks by 0,25% trypsin-EDTA, collected in 50-mL-
falcon tubes, and centrifuged at 1000 rpm for 10 min. 
The cell pellet was homogenized in full DMEM 
medium, transferred into 75-cm
2-
culture flasks, and 
incubated at 37°C in a humidified atmosphere of 5% 
carbon dioxide.
20
 
  
Transfection of BMSCs by Green Fluorescent 
Protein  
In order to track the stem cells in vivo, BMSCs 
were transfected with pEGFP-N2 vector including 
green fluorescent protein (GFP) encoding gene 
(ClonTech, USA) by using Metafectene Pro 
transfection reagent (Biontex Laboratories GmbH, 
Germany). 5×10
5
 MSCs were transferred into 75-cm
2
-
flasks and incubated at 37°C and 5% CO2 till they 
became 70-80% confluent. On the day of transfection, 
the medium was discarded from the flasks, and 12 mL 
of blank DMEM medium was transferred onto the 
cells. 6 µg plasmid DNA and 20 µL of transfection 
reagent were mixed in order to form transfection 
complexes, and these complexes were transferred 
dropwise onto the cells. The flasks were gently 
swirled to ensure the uniform distribution of the 
complexes. The transfected cells were incubated at 
37°C in 5% CO2 incubator for 4 h, and then medium 
containing transfection complexes were replaced with 
fresh full DMEM medium. 72 h after the transfection, 
transfected cells were visualized under the fluorescent 
microscope.
21
 
 
Characterization of BMSCs  
Cells were incubated with antibodies recognizing 
NG2 PE (Beckman Coulter), CD45 PC5 (Beckman 
Coulter, Marsillia, France), CD73 PE (Becton-
Dickinson, Bioscience Pharmingen, San Diego, CA, 
USA), and CD105 FITC (Serotec, Oxford, UK). 
Fluorescence histograms were obtained by recording 
2x10
4 
cells/sample at a flow rate of approximately 200 
cell events/s. Experiments were performed with the 
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FACS Canto II device and flow cytometric data were 
examined using the FACS DIVA software (BD 
Bioscience, San Jose, USA).
24
 Flow cytometry 
analysis revealed that expression levels of MSC-
specific CD105, CD73, and NG2 antigens were 
significantly increased and none of the cells were 
stained with CD45 hematopoietic marker antigen.
19
 
4',6-diamidino-2-phenylindole (DAPI) staining was 
used to determine the number of nuclei and to assess 
gross cell morphology (Figure 2). 
 
Histopathological and Immunohistochemical 
Analysis of Lung Tissue 
Lungs of each mouse were removed and examined 
for histomorphological changes. Mice were 
anesthetized with the overdose of ketamine after 1 
week of the last MSCs and saline administration. Two 
investigators, who were blinded to the treatment 
groups, interpreted the histopathological changes. 
Tissue specimens were obtained from the middle zone 
of the left lung of mice. Samples were fixed in 10% 
formalin for light microscopic evaluations. After 
fixation, samples were embedded in paraffin and 
serial sections of 5-µm thickness were prepared. 
Sections were stained with hematoxylin and eosin 
(H&E), and masson’s trichrome stain. In histological 
analyses, diameter and wall thickness of terminal 
bronchiol and terminal artery, and 
peribronchovascular collagen depositions were 
evaluated. For immune cell infiltration, paraffin 
sections were stained by CD3 (1:100, Santa Cruz, 
USA), CD4 (1:100, Santa Cruz, USA), CD8 (1:100, 
Santa Cruz, USA), CD20 (1:100, Santa Cruz,USA), 
CD 68 (1:100, Novus, USA), and Neutrophil Elastase 
(1:100 Novus, USA) antibodies for 
immunhistochemical analyses. Seconder marking 
sections were finally stained with diaminobenzidine 
(DAB) (Invitrogen, USA). Immune cell densities were 
assessed in 10 different areas per section and 
expressed as percentage. Photomicrographs were 
taken with JVC TK-890-E camera (JVC, Japan) that 
was adapted on Olympus BH-2 RFCA model 
microscope (Olympus Optical, Japan). The 
histological analysis was carried out with 
UTTHSCSA Image Tool for Windows Version 3.00 
Software (UTHSCSA Dental Diagnostic Science, 
USA).  
 
 
Measurements of Cytokines and Differential Cell 
Count in Bronchoalveolar Lavage Fluid  
Bronchoalveolar lavage fluid (BALF) was 
immediately collected from euthanized mice by 
instillation and recovery of 1 mL 0,09% NaCl through 
the tracheal cannula. BALF was centrifuged at 3000 × 
g for 10 min and supernatant was removed and stored 
at −80◦C. Levels of Interleukin-2, TNF- α, and IFN-γ 
were quantified in BALF by using standard ELISA 
protocols with the help of commercial mouse 
Interleukin-2, TNF-α, IFN- γ kits (eBioscience Mouse 
ELISA kit, USA). 
Detection levels were 2.0 pg/mL for IL-2, 8.0 
pg/mL for TNF-α and 15 pg/mL for INF- γ 
Histological smear samples were also prepared. A 
differential cell count was performed by using May-
Grünwald Giemsa staining and cells were classified as 
eosinophils, neutrophils, and lymphocytes on the basis 
of morphologic criteria and staining characteristics. 
Differential cell counts were performed in a blinded 
fashion by counting at least 200 cells per slide under 
light microscopy.  
 
Statistical Analysis  
SPSS 15 package program was used for statistical 
analyses (SPSS Inc, Chicago, Illinois, USA). The data 
were presented as mean±standard error of mean 
(SEM). All data were analyzed by using one-way 
analysis of variance (ANOVA) posthoc Bonferroni 
test. p<0,05 was considered statistically significant.  
 
RESULTS 
 
Characterization and Migration of BMSCs   
Flow cytometry analysis revealed that expression 
levels of MSC-specific CD105, CD73, and NG2 
antigens were significantly increased and none of the 
cells were stained with CD45 hematopoietic marker 
antigen (CD105; %99,7, CD73; %99,9, NG2; %98,9, 
CD 45;  %0,1). According to the results of the 
confocal microscopy, group III mice did not have 
significant BMSCs in their lung tissue, while it was 
observed that all mice in group II had green dots and 
this finding indicates that labeled BMSCs migrated to 
the lung tissues of group II mice upon their 
intraperitoneal administration (Figure 2).   
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Histopathological and Immunohistochemical 
Analysis of Lung Tissue 
Morphometric measurements of terminal bronchiole 
(TB) and terminal arteriole (TA) diameters and wall 
thicknesses of the groups are presented in Table 1 and 
Figure
 
3,
 
4.
 
The
 
TB
 
wall
 
thicknesses
 
and
 
diameters
 
were significantly lower (p<0.05) in group II when 
compared to group IV, whereas TA wall thicknesses 
and TA diameters
 
were
 
similar
 
to
 
group
 
IV.
 
Peribronchovascular collagen deposition significantly 
was decreased in group II compared to group IV 
(Table 1) (p<0.05). Measurements of the total amount 
of immune cell airway infiltration
 
(lymphocytes,
 
macrophages
 
and neutrophils) and their 
immunophenotyping are presented in Table 2 and 
Figure 5, 6. The percentage of all immune cells 
 
 
 
significantly was increased in group IV compared to 
group I (control group) (p<0.05). Additionally, the 
number of immune cells significantly decreased in 
group II mice compared to group IV mice (p<0.05).   
 
Cytokine Levels and Differential Cell Count in 
BALF  
All of the cytokine levels (IL-2, IFN-γ, TNF- α) of 
group II were significantly lower compared to group 
IV (Table 3, Figure 7) (p<0.05). The number of 
eosinophils, lymphocytes, and neutrophils in BALF 
significantly was reduced in group II (BO developed 
and BMSCs treated group) compared to group IV 
(BO-developed and saline treated group) (Table 4, 
Figure 8) (p<0.05).  
 
 
   
   
A1                                               B2 
Group II 
 
A2                                                        B2 
Group III 
Figure 2. Confocal microscopic images after intraperitoneal injection of allogeneic bone marrow-derived mesenchymal stem 
cells (MSCs) in bronchiolitis obliterans mice model;  non-bronchiolitis obliterans developed and 1x106 allogeneic bone 
marrow-derived MSCs- injected group (Group III) did not have significant bone marrow-derived MSCs in their lung tissue 
while it was observed that all mice in bronchiolitis obliterans-developed and 1x106 bone marrow-derived --MSCsinjected 
group (Group II) had green dots, which indicates that labeled bone marrow-derived MSCs migrated to the lung tissues of 
group II mice. 
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Table 1. Histopathological findings after intraperitoneal injection of allogeneic bone marrow-derived mesenchymal stem cells 
in mice model of bronchiolitis obliterans 
 I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group (mean±SD) 
  Group I 
(Control) 
(Mean ±SD) 
Group II 
(Bronchiolitis 
Obliterans+, 
Mesenchymal 
stem cell) 
(Mean ±SD) 
Group III 
(Bronchiolitis 
Obliterans -, 
Mesenchymal stem 
cell) 
(Mean ±SD) 
Group IV 
(Bronchiolitis 
Obliterans +, Saline) 
(Mean ±SD) 
Diameter of terminal bronchiole (µm)  118.9±38.43 125.78±14.37 116.31±9.82 124.38±18.27 
Wall thickness of terminal bronchiole (µm²)  10.52±1.28* 8.95±0.77* 9.39±0.95* 32.94±5.15 
Diameter of terminalarteriol (µm)  59.19±3.77 66.91±2.6 57.61±5.99 70.97±8.78 
Wall thickness of terminalarteriol (µm²)  6.59±0.80 8.24±1.87 7.88±0.41 8.61±1.45 
Peribronchiolar collagen deposition (µm²/µ m) 3.49±0.20* 3.71±0.36* 3.44±0.22* 9.33±2.14 
Periarteriolar collagen deposition (µm²/µm) 3.57±0.63* 5.1±0.69* 4.93±0.90* 16.67±1.86 
*p<0.05 compared to group BO +, Saline (Group IV)  
 
 
 
 
 
 
Table 2. Immunohistochemical findings of the intraperitoneal injection of allogeneic bone marrow-derived mesenchymal 
stem cells in bronchiolitis obliterans mice model 
I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group (mean±SD)  
   Group I 
(Control) 
(Mean ±SD) 
Group II 
(Bronchiolitis 
Obliterans+, 
Mesenchymal stem cell) 
(Mean ±SD) 
Group III 
(Bronchiolitis Obliterans 
-, Mesenchymal stem cell) 
(Mean ±SD) 
Group IV 
(Bronchiolitis Obliterans 
+, Saline) 
(Mean ±SD) 
CD3 (%)  0.11±0.01* 0.29±0.01* 0.16±0.02* 0.50±0.02 
CD4 (%)  0.14±0.01* 0.30±0.01* 0.18±0.02* 0.46±0.03 
CD8 (%)  0.11±0.01* 0.32±0.02* 0.16±0.01* 0.44±0.03 
CD20 (%)  0.13±0.02* 0.26±0.01* 0.13±0.01* 0.41±0.01 
CD68 (%)  0.12±0.01* 0.25±0.02* 0.14±0.02* 0.37±0.02 
Neutrophil Elastase (%)  0.14±0.01* 0.24±0.01* 0.16±0.02* 0.42±0.01 
*p<0.001 compared to group bronchiolitis obliterans +, Saline (Group IV)  
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Figure 3. Light microscopic findings after intraperitoneal injection of allogeneic bone marrow-derived mesenchymal stem 
cells in bronchiolitis obliterans mice model  groups (40X) 
I; Control, II; bronchiolitis obliterans-developed and  bone marrow-derived mesenchymal stem cells-injected group, III; non-
bronchiolitis obliterans and bone marrow-derived mesenchymal stem cells -injected group, IV; bronchiolitis obliterans-
developed and saline-injected group. In representative histological images lung tissues were stained with hematoxylin & eosin 
(H&E) (A; 1st row) and Masson’s Trichrome (B; 2nd row). In control group; light microscopic findings revealed a regular, 
normal bronchiole wall thickness, bronchiole lumen, collagen deposition (A1,B1). In group IV; H&E staining revealed 
thickened bronchiole wall, reduction of diameter of bronchiole lumen and inflammatory cells around the bronchiole wall 
(black arrow, A4). In group IV; Masson’s trichrome staining revealed increased periarteriolar collagen deposition (blue 
color- green arrow, B4). In group II, bronchiole wall thickness and peribronchiolar and periarteriolar collagen deposition 
(A2,B2) were significantly less than group IV (A4,B4) and no statistical difference was found in terms of the diameter-wall 
thickness of arteriol and diameter of bronchiol between both groups. 
 
Figure 4. Correlation graphics of histopathological findings in the study of intraperitoneal injection of allogeneic bone 
marrow-derived mesenchymal stem cells in bronchiolitis obliterans mice model  
 I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group. 
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Figure 5. The immunohistochemical staining after the intraperitoneal injection of allogeneic bone marrow- derived 
mesenchymal stem cells in bronchiolitis obliterans mice model  groups (40X) 
  I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; 
non-bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group. Representative pictures show the immunohistochemical staining of CD3, CD4, 
CD8, CD20, CD68, neutrophil elastase. Black arrows indicate the staining of group IV in comparison with group II and 
group III. The percentage of all immune cells significantly was increased in group IV compared to group I (control group). 
Additionally, the number of immune cells significantly decreased in group II mice compared to group IV mice.   
 
 
 
 
Figure 6. Correlation graphics of immunohistochemical findings in the study of intraperitoneal injection of allogeneic bone 
marrow-derived mesenchymal stem cells inbronchiolitis obliterans mice model  
 I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group. 
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Figure 7. Correlation graphics of cytokine levels in the study of intraperitoneal injection of allogeneic bone marrow-derived 
mesenchymal stem cells in bronchiolitis obliterans mice model  
 I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group. 
 
 
 
Figure 8. Correlation graphics of differential cell counts of bronchoalveolar lavage fluid in the study of intraperitoneal 
injection of allogeneic bone marrow-derived mesenchymal stem cells in bronchiolitis obliterans mice model  
 I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group. 
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Table 3. Cytokine levels in bronchoalveolar lavage fluid (BALF) (pg/ mL) in the study of intraperitoneal injection of 
allogeneic bone marrow-derived mesenchymal stem cells in bronchiolitis obliterans mice model  
 I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group (mean±SD) 
  Group I 
(Control) 
(Mean ±SD) 
Group II 
(Bronchiolitis 
Obliterans+, 
Mesenchymal stem 
cell) 
(Mean ±SD) 
Group III 
(Bronchiolitis Obliterans 
-, Mesenchymal stem cell) 
(Mean ±SD) 
Group IV 
(Bronchiolitis Obliterans 
+, Saline) 
(Mean ±SD) 
IL-2 (BALF)  0.10±0.04 0.11±0.04* 0.15±0.05* 0.40±0.04 
TNF-α (BALF)  0.16±0.03 0.12±0.02* 0.18±0.05* 0.37±0.09 
IFN-γ (BALF)  0.12±0.02 0.15±0.04* 0.19±0.02* 0.38±0.06 
*p<0.05 compared to group bronchiolitis obliterans +, Saline (Group IV)  
  
Table 4. Differential cell counts of bronchoalveolar lavage fluid (BALF) in the study of intraperitoneal injection of allogeneic 
bone marrow-derived mesenchymal stem cells in bronchiolitis obliterans mice model 
I; Control; II, bronchiolitis obliterans-developed and bone marrow-derived mesenchymal stem cells -treated group, III; non-
bronchiolitis obliterans developed and bone marrow-derived mesenchymal stem cells-given group, IV; bronchiolitis 
obliterans-developed and saline-treated group (mean±SD) 
% Cells Group I 
(Control) 
(Mean ±SD) 
Group II 
(Bronchiolitis 
Obliterans+, 
Mesenchymal stem 
cell) 
(Mean ±SD) 
Group III 
(Bronchiolitis Obliterans 
-, Mesenchymal stem cell) 
(Mean ±SD) 
Group IV 
(Bronchiolitis 
Obliterans +, Saline) 
(Mean ±SD) 
Eosinophils  3.0±0.44* 17±1.97*# 3.8±0.67* 34±3.02# 
Neutrophils  3.0±0.45* 8.1±1.31*# 4.5±0.71* 13.6±1.05# 
Lymphocytes  13.6±1.12* 15.5±1.93* 16.4±1.15* 25.1±3.37# 
*p<0.05 compared to group bronchiolitis obliterans +, Saline (Group IV) 
#p<0.05 compared to group control (Group I) 
 
 
DISCUSSION 
 
The pathogenesis of BO has been extensively 
studied in both populations which were either organ 
transplanted or not transplanted. In the pathogenesis of 
BO, bronchiolar epithelial cells are damaged, and T 
lymphocytes and neutrophils are recruited to the site of 
the injury. Various cytokines and chemokines such as 
TNF- α, IL-2, IL-8, and regulated on activation, normal 
t cell expressed and secreted  (RANTES)  are activated 
and create an inflammatory response. The repeated and 
persistent inflammation can lead to an excessive 
fibroblastic response which can further cause the 
peribronchiolar fibrosis and obliteration of airways.
23-25
  
 
Stem cells are undifferentiated cell groups that show 
varying degrees of self-renewal and differentiation 
capacity. MSCs are capable of adopting the 
morphology and phenotype of parenchymal cells of 
many non-hematopoietic tissues, including the lung 
tissue,
26,27
 where they can differentiate into bronchial 
epithelial cells
28
 and alveolar type I and II 
pneumocytes.
26,27,29
 Furthermore, MSCs exhibit 
immunosuppressive properties through a mechanism 
that involves the paracrine inhibition of T- and B-cell 
proliferation.
30
 Recently, most studies have investigated 
the role of MSCs on tissue repair, regeneration, and 
remodeling in respiratory diseases.
31,32
 Stem cell 
therapy appears to be a promising strategy for the 
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treatment of many respiratory diseases which have no 
effective treatment, such as acute lung injury (ALI)
16
 
and its severe forms such as acute respiratory distress 
syndrome (ARDS),
17
 and chronic obstructive 
pulmonary disease (COPD).
15
 Some clinical trials test 
the safety and feasibility of cell-based therapy in 
respiratory diseases. Recently, a Brazilian research 
group has tested the safety of bone marrow-derived 
mesenchymal stem cell administration in four patients 
with severe COPD. However, they did not show the 
efficacy of the stem cell therapy.
33
 On the other hand, 
another clinical study suggested that the intratracheal 
transplantation of allogeneic human umbilical cord 
blood-derived MSCs is safe and feasible for 
bronchopulmonary dysplasia in preterm infants.
34 
BO is a devastating disease with high mortality 
rate and no effective-curative therapy can reverse or 
delay the natural course of this disease. MSC therapy 
could be a possible therapeutic tool for BO, because 
MSCs can yield anti-inflammatory and 
immunmodulatory effects, and they can also inhibit the 
fibrogenesis. A recent study has shown that the 
treatment with placenta-derived human mesenchymal 
stem cells (PMSCs) can reduce the development of BO 
in a heterotopic tracheal transplantation murine 
model.
35
 Grove et al.
36
 also evaluated the effects of 
bone marrow-derived MSCs on the BO murine model. 
They carried out a retro-orbital injection of 5x10
5 
cells 
in allogeneic mice. They detected a 60% decrease in 
the intraluminal obstruction in the experimental group 
of animals, which were sacrificed at the 7 and 14 days 
of the MSCs administration, compared to controls. 
There are many controversial studies in the literature, 
which have evaluated effects of stem cell therapy in 
experimental murine model of BO. Espinel at al. 
showed that the regular injection of epididymal adipose 
tissue-derived stem cells did not significantly reduce 
the severity of allograft inflammation in seven days. 
However, it increased the allograft inflammatory 
process in heterotopic tracheal transplant bronchiolitis 
obliterans model in 21 days.
37
 In their study, they 
obtained MSCs from epididymal adipose tissue and it 
was suggested that different sources of MSCs may 
change the immunomodulating potency due to the 
standard production of growth factors and interleukins. 
In our study, we observed that BMSCs administered by 
intraperitoneal route significantly decreased TH1 
immune cytokine (such as IL-2, TNF- α and IFN- γ 
levels in group II (BO-developed and BMSCs-treated 
group) compared to group IV (BO-developed and 
saline-treated group). MSCs prevent fibrosis at an early 
stage of lung injury by reducing the neutrophil influx, 
inflammation, and collagen deposition. In a late stage 
of lung injury, MSCs can prevent the fibrosis by 
downregulating the cytokines such as IL-1β, TGF- β, 
VEGF, IL-6, TNF-α, and nitric oxide synthase 
(NOS).
38
 The bleomycin-induced lung fibrosis model is 
a well-characterized and commonly used model for 
understanding the mechanism of MSCs. It was shown 
that MSCs inhibited the inflammation and the fibrosis 
in the lung tissue in animals with bleomycine-induced 
lung injury by inhibiting the production of two 
fundamental pro-inflammatory cytokines such as IL-1 
and TNF-α and reducing the neutrophil and lymphocyte 
trafficking in the lung.
39
 Furthermore, the treatment 
with MSCs decreased the bleomycin-mediated collagen 
deposition and decreased the levels of TGF-β, MIP, and 
IFN-γ cytokines.40 Even though some researchers claim 
the antifibrotic effect of MSC, some others support the 
idea that MSC therapy have profibrotic effects.
41,42
 In 
our study, we showed that periarteriolar and 
peribronchiolar collagen deposition and wall thickness 
of terminal bronchiole were significantly decreased in 
Group II (BO-developed and BMSCs-treated group) 
compared to the Group IV (BO-developed and saline-
treated group) in murine model of BO. 
The optimal route for stem cell transplantation in a 
lung injury has not yet been determined. In contrast to a 
normal lung tissue, an injured lung produces soluble 
factors, which can cause MSCs to proliferate and 
migrate towards an injured lung.
43
 It has recently been 
shown that human MSCs administered by 
intraperitoneal injection could be implanted in the 
lungs of newborn rats and cells could effectively 
prevent the hyperoxia-derived lung injury in rats.
44
 
Several studies have demonstrated that the pulmonary 
engraftment of MSCs in the lung tissue is very low and 
thus the effects of these cells on organ systems are 
currently attributed to a paracrine effect. In other 
words, secretion of soluble factors in different diseases 
can modulate various immune responses such as 
inhibition or activation of dendritic cells and T 
lymphocytes, and inflammatory cytokine secretion 
(TNF- α, IFN-γ), and increase in the release of anti-
inflammatory cytokines (IL-10, IL-4).
39,45,46
 This 
mechanism was first identified when MSCs were 
systemically administered and they could inhibit the 
expression of several pro-inflammatory and pro-
Sakine Işık, et al. 
216/ Iran J Allergy Asthma Immunol, Summer 2017                                Vol. 16, No. 3, June 2017 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
fibrogenic cytokines in acute lung injury and 
pulmonary fibrosis models.
29,39
 TNF- α, a mesenchymal 
growth factor that is known to participate in matrix 
remodeling, has been shown to be elevated in the early 
stage of BO in both human and animal studies.
29,47
 
Upregulation of TH11 cytokines and chemokines, such 
as IFN- γ and IL-2, were also observed in post-
transplant airway obliteration.
48
 In the present study, 
BMSCs were intraperitoneally administered to mice in 
order to evaluate the migration. In our study, we 
showed that the intraperitoneally injected BMSCs 
migrated to the injured lung tissue in group II (BO-
developed and BMSCs-treated group). Similar to the 
literature, cells showed beneficial effects on lung 
histopathology and TH1 immune response in murine 
model of BO. In our opinion, beneficial effects of 
intraperitoneally injected BMSCs on the lung tissue 
may be related the autocrine or paracrine effects of 
these stem cells on inflammation and fibrosis. 
In the present study, immunohistochemical and 
histopathological examinations demonstrated that 
intraperitoneally administered BMSCs  migrated to the 
lung tissue, and they have beneficial effects on 
inflammation and fibrogenesis in murine model of BO. 
However, further experimental studies are necessary in 
order to support the effective transfer of cellular 
therapy for BO. Additionally, many new trials will be 
necessary to assess the favorable effects of the use of 
BMSC therapy in human BO. However, route of 
administration, as well as the cell type, the best dose to 
be administered, the nature of the signals involved in 
MSC recruitment to the lung, the extent of MSC 
engraftment, and the role of the injury or disease in 
these processes are all issues to be clarified. 
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